Fisetin Side Effects and Safety: What the Trials Show (2026)

What is the honest safety picture for fisetin?

Human fisetin safety data remain limited, heterogeneous and often short-term. No consistent severe-toxicity signal has emerged from the small trials available, but that is not proof of safety for chronic use, combination regimens or people excluded from those trials. Reported symptoms in consumer discussions cannot establish a reliable side-effect incidence.

Pregnancy, breastfeeding, childhood, cancer treatment, organ disease and interaction-sensitive medication are important situations for individual clinical review. For the larger evidence base, see our clinician's guide.

Fisetin safety: evidence versus assumptions

Question	What can be concluded
Are short-term doses tolerated?	Small human trials offer some short-term tolerability observations, but study populations, formulations and adverse-event collection differ.
What is the common-side-effect rate?	Reliable pooled human incidence estimates are unavailable; spontaneous online reports cannot establish rates or causality.
Is long-term, high-dose use safe?	Not established, including for repeated experimental pulses or complex supplement stacks.
What about medicines?	Mechanistic interaction signals exist, but controlled human coadministration studies are inadequate. See the medication-specific review.
Pregnancy or breastfeeding?	No adequate supplemental-fisetin safety evidence. Distinguish ordinary foods from concentrated supplements; see pregnancy and breastfeeding.

Do not interpret an unreported event as a zero-risk result. Small studies are not powered to exclude uncommon serious adverse reactions.

What does the overall evidence base look like?

Fisetin's safety record comes from three sources: toxicology and animal studies, clinical trials, and the accumulated consumer experience of people taking commercial capsules over roughly a decade.

Toxicology

Experimental toxicology findings provide preliminary information, but animal safety margins cannot establish safe long-term supplemental doses for humans [2] [3].

Clinical trials

A September 2026 clinical-translation review identified 34 registered fisetin studies, but only six were completed and four had results available at its August 2026 search cutoff [9]. These studies span different populations, doses, schedules and co-interventions, so they do not create one well-characterized safety dataset.

COVID-FIS, terminated for futility, reported no serious adverse event clearly attributed to fisetin in its small older-adult population [1], while the completed knee-osteoarthritis trial did not identify a clear adverse-event excess versus placebo [6]. Those are reassuring signals within specific trials, not proof that chronic daily fisetin is safe across populations.

Study-by-study safety observations

These studies used different populations, doses, formulations and monitoring periods. They cannot be combined into a reliable incidence estimate for consumer supplements.

Human study	Exposure and follow-up	What adverse-event data show	Limits
Knee osteoarthritis trial [6] [14]	Registry actual enrollment: 75; April 2025 OARSI abstract: 74 randomized (34 fisetin, 40 placebo), with the denominator discrepancy unresolved. Fisetin was tested at roughly 20 mg/kg/day for three two-day cycles separated by 28 days off, with 12-month follow-up.	At least one treatment-emergent adverse event was reported in the registry for 28 fisetin participants and 33 placebo participants. The OARSI abstract reported 185 adverse events overall, mostly minor, plus four serious events involving unrelated surgeries (two in each arm); there was no significant between-group difference in event incidence.	This particular intermittent schedule does not establish chronic daily or high-dose stack safety. Registry results, not a verified peer-reviewed outcomes article.
Human FF-20 crossover pharmacokinetic study [12]	15 healthy volunteers received single doses of unformulated fisetin and a distinct hybrid-hydrogel formulation at crossover visits, separated by a 10-day washout.	No adverse events were reported during the single-dose study.	A small pharmacokinetic study with unequal amounts of actual fisetin between formulations cannot establish repeated-dose or long-term safety.
COVID-FIS trial [1]	20 older skilled-nursing residents enrolled; the trial was terminated for futility.	Posted trial observations did not identify a serious adverse event clearly attributed to fisetin.	A small terminated trial in a specific ill population does not exclude uncommon harms or establish benefit.
CVID-associated GLILD pilot (May 2026 meeting abstract) [13]	Ten adults randomized to fisetin 20 mg/kg or placebo on days 0–1 and 28–29, with 180-day follow-up; the linked parent registry lists planned enrollment of 20.	The conference abstract reported no adverse events.	Conference-only, small and disease-specific; allocation details and complete adverse-event data from the unfinished parent trial are unavailable.

Interpretation: Short-term tolerability observations cannot be extrapolated to years of routine use, pregnancy, cancer treatment or combinations with prescription medicines.

Post-market supplement use

Commercial fisetin use does not provide a reliable adverse-event incidence rate. Dietary supplements do not have the same systematic safety-surveillance structure as prescription medicines, and absence of widely publicized reports cannot establish long-term safety.

Which minor symptoms have been reported?

Minor symptoms such as gastrointestinal upset, headache or fatigue are mentioned in supplement discussions and some clinical contexts, but the available fisetin trials are too small and heterogeneous to define a reliable "most common side effects" profile.

Gastrointestinal upset

Nausea, cramping and loose stools are mentioned in some supplement reports, but controlled fisetin studies have not established their incidence, severity, cause or relationship to fasting or product quality. Do not assume these symptoms are harmless or specific to fisetin. Human trials have not established that taking fisetin with dietary fat prevents gastrointestinal symptoms or improves absorption. If a supplement causes nausea or other gastrointestinal symptoms, changing the meal context may alter tolerability, but persistent or significant symptoms are a reason to stop and seek clinical advice. See our how and when to take fisetin article for the current food-effect evidence.

Headache

Headache is sometimes mentioned in anecdotal supplement reports, but controlled fisetin studies have not established a characteristic incidence, dose relationship or prevention strategy. New or severe headaches warrant clinical evaluation rather than assuming they are an expected effect.

Fatigue or drowsiness

Fatigue and drowsiness are sometimes described anecdotally, but they have not been established as a characteristic fisetin adverse-effect pattern in controlled trials. If new drowsiness occurs after a supplement, avoid driving or other safety-sensitive activities until the cause is clear.

Sleep changes

Sleep effects have not been adequately characterised in controlled fisetin trials. Anecdotal reports cannot establish whether fisetin improves or disrupts sleep. If sleep changes follow a new supplement, discuss whether to continue it and whether another cause needs assessment; no fisetin-specific timing strategy has been validated.

Note: Reported symptom frequency cannot currently be estimated reliably from controlled fisetin trials; infographics assigning “common” or “rare” rates would overstate the evidence.

What rare but reported concerns exist?

Skin flushing or rash

A reliable fisetin-specific incidence of flushing, rash or allergy has not been established in controlled human research. If a new rash, swelling or other suspected hypersensitivity occurs after a supplement, stop taking it and seek medical advice; urgent symptoms such as breathing difficulty require emergency care.

Mild lightheadedness

Fisetin has vasorelaxant activity in some animal and isolated-vessel experiments, but a clinically important blood-pressure effect in humans has not been established. Dizziness or lightheadedness after a supplement may have many causes, including prescription-drug effects; do not assume fisetin has lowered your blood pressure. Seek clinical guidance, especially if taking antihypertensive medication. Our dedicated blood pressure article covers this in more detail.

Palpitations

Palpitations have not been established as a fisetin-specific adverse reaction or assigned a reliable incidence in controlled trials. If they develop after starting a new supplement, stop the product and consult a clinician; chest pain, fainting or severe shortness of breath require urgent assessment. Do not attribute symptoms to caffeine or anxiety without evaluation.

Does fisetin cause or treat cancer?

This question comes up in both directions and deserves a straight answer.

Does fisetin cause cancer?

There is no established evidence that concentrated fisetin supplementation causes cancer, but long-term human safety studies are insufficient to exclude uncommon or delayed risks. Preclinical anticancer effects cannot resolve that uncertainty or justify its use as cancer prevention [7].

Can fisetin treat cancer?

Preclinically, there's substantial evidence of activity against breast, prostate, and other cancer models [7]. Clinically, no human oncology trial has shown that oral fisetin at supplement doses changes cancer outcomes. Fisetin is not a cancer treatment and shouldn't replace prescribed oncology care.

Cautions in active cancer

If you have active cancer, don't start fisetin without your oncology team's input. A few specific concerns apply. The senolytic mechanism sits mechanistically close to cytotoxic activity, and interactions with chemotherapy, targeted therapy, or immunotherapy aren't well characterised. Fisetin's CYP2C8 activity may also affect how some anti-cancer drugs are metabolised — our drug interactions article covers this. And some preclinical work has explored fisetin as a chemosensitiser, meaning it might amplify the effects of concurrent chemotherapy — which could help or hurt depending on the specific regimen.

How does fisetin affect immune function?

Fisetin changes inflammatory signalling in several experimental systems, but those effects do not establish whether supplementation improves or suppresses immune function in people. Small human trials, including COVID-FIS, cannot exclude uncommon immune-related harms or define interactions with immunosuppressants [1]. People taking transplant medicines, biologics or other immunosuppressants should discuss concentrated fisetin with their specialist.

Is there a risk from very high single doses?

Some monitored clinical trials have used intermittent doses around 20 mg/kg/day, but their enrolment criteria, co-medications, schedules and safety monitoring differ. These limited trial experiences do not prove that the same dose is safe for unsupervised use or that still higher doses offer no added exposure. Human dose-proportionality and long-term safety data remain insufficient. Do not extrapolate a research regimen into a self-treatment schedule.

Who should avoid fisetin or use extra caution?

The human safety database is still too limited to define every high-risk group, but extra caution is reasonable where physiology, medication interactions or lack of data make uncertainty more consequential.

Pregnancy and breastfeeding — concentrated fisetin supplementation has not been adequately studied. Dietary fisetin from ordinary foods is a different exposure from supplement doses. See our pregnancy article.

Children and adolescents — therapeutic-dose fisetin has not been established for pediatric use.

People taking anticoagulant, antiplatelet or other interaction-sensitive medication — human interaction studies are sparse, so the specific medication list should be reviewed with a prescriber or pharmacist rather than assuming compatibility.

People receiving cancer therapy — fisetin is not a cancer treatment, and potential interactions with chemotherapy, targeted therapy, radiotherapy or immunotherapy have not been adequately characterized.

People with chronic kidney disease — a Mayo Phase 2 study (NCT03325322) tested a short fisetin course in advanced diabetic/chronic kidney disease but was suspended for lack of funding and did not establish a clinical benefit or a CKD-specific safety profile. [10]

People with significant liver disease or complex multimorbidity — long-term pharmacokinetics and safety have not been adequately defined in these populations.

People preparing for surgery or procedures — tell the surgical team about fisetin and other supplements. There is no fisetin-specific evidence establishing a universal “stop exactly seven days before surgery” rule; perioperative instructions should come from the treating team.

People with a known allergy to the product or its ingredients — avoid the relevant product.

Further reading: the clinical-trial dosing evidence. Current trial data remain too limited to settle long-term safety.

What we still don't know

Long-term safety remains incompletely characterized. Human research includes daily and intermittent regimens, but no large controlled dataset establishes the safety of routine fisetin supplementation over years.

How chronic fisetin exposure affects liver function in humans is untested — flavonoids as a class are generally hepatoprotective at moderate doses but can be hepatotoxic at very high sustained doses, and fisetin-specific human data don't exist.

Whether fisetin at supplement doses affects fertility, sperm parameters, or menstrual cycle regularity hasn't been studied in humans.

Safety in specific high-risk groups remains under-characterized. Small and ongoing studies include older adults and some chronic-disease populations, but they are not large enough to define subgroup risk reliably.

How fisetin interacts with commonly prescribed cardiovascular medications, such as statins, beta blockers, or ACE inhibitors, at typical doses hasn't been characterised.

Bottom line

Human fisetin studies have not revealed a consistent severe-toxicity signal, but the evidence base is small, heterogeneous and often short-term. A September 2026 review identified 34 registered fisetin-related clinical studies, yet many remain ongoing and several use combination products or multimodal interventions. This is not enough to define a precise long-term adverse-event rate for routine supplement use.

Symptoms such as gastrointestinal upset, headache or fatigue are discussed in consumer reports and some study contexts, but they should not be presented as a well-quantified characteristic side-effect profile. Pregnancy, breastfeeding, significant kidney or liver disease, cancer treatment and interaction-sensitive medication are situations where clinical review is particularly important.

Fisetin should not replace prescribed therapy for any serious medical condition.